Lindsay Rosenwald
Chief Executive Officer at FORTRESS BIOTECH, INC.
Net worth: 6 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Weiss | M | 58 |
Cyprium Therapeutics, Inc.
 Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then.
Helocyte, Inc.
 Helocyte, Inc. Miscellaneous Commercial ServicesCommercial Services Helocyte, Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients and Triplex. The company was founded by Donald J. Diamond in 2015 and is headquartered in New York, NY.
Baergic Bio, Inc.
 Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY.
Cellvation, Inc.
| 19 years |
| Neil Herskowitz | M | 67 | 10 years | |
| Xiao Qin Lu | M | 49 | 12 years | |
| James Oliviero | M | 48 | 21 years | |
| David Jin | M | 34 | - | |
| Frank Taffy | M | - |
Helocyte, Inc.
Helocyte, Inc. Miscellaneous Commercial ServicesCommercial Services Helocyte, Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients and Triplex. The company was founded by Donald J. Diamond in 2015 and is headquartered in New York, NY.
Cellvation, Inc.
| 9 years |
| William Gray | M | 36 | 8 years | |
| Manuel Litchman | M | 70 | 7 years | |
| Jay Kranzler | M | 66 |
Baergic Bio, Inc.
Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY. | 7 years |
| Adam Chill | M | 56 | 10 years | |
| Claude Maraoui | M | 57 | 10 years | |
| Jaclyn Jaffe | F | - | - | |
| J. Lobell | M | 61 |
Paramount BioCapital, Inc.
 Paramount BioCapital, Inc. Investment ManagersFinance Paramount BioCapital, Inc. is an alternative investment manager. The private company is based in New York, NY and has subsidiaries in the United States. | 19 years |
| Malcolm Hoenlein | M | 80 | 10 years | |
| Lung S. Yam | M | - |
Cyprium Therapeutics, Inc.
Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then. | 7 years |
| Brian Achenbach | M | 59 | 7 years | |
| Michael S. Spector | M | - |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | - |
| Alexandra MacLean | M | 57 | 3 years | |
| George Avgerinos | M | 71 | 11 years | |
| Ramsey Alloush | M | 39 | - | |
| Ernest Galvan | M | 62 | - | |
| Kevin Lorenz | M | 59 | 5 years | |
| Justin Smith | M | 49 | 3 years | |
| Samuel Berry | M | - | 8 years | |
| Greg Furrow | M | - | 5 years | |
| Joseph Benesch | M | 57 | 3 years | |
| Michael Zelefsky | M | 63 | 7 years | |
| Curtis Oltmans | M | 60 | 3 years | |
| Dov Klein | M | 72 | 9 years | |
| Miranda Toledano | F | 47 | 3 years | |
| Faith Charles | F | 62 | 2 years | |
| James Murphy | M | 67 | - | |
| Christian Béchon | M | 63 | 6 years | |
| Jimmie Harvey | M | 72 | 16 years | |
| Barry Salzman | M | 62 | 8 years | |
| Jessica Yeaman | F | - | 6 years | |
| Nicole McCloskey | F | - | - | |
| Robert Sexton | M | - | 2 years | |
| Rick Bodmer | M | - | 2 years | |
| Srinivas Sidgiddi | M | - | 3 years | |
| Paul Brooke | M | 77 |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | 6 years |
| Robert Nevin | M | 56 | - | |
| Daniel DiPietro | M | - |
Paramount BioCapital, Inc.
Paramount BioCapital, Inc. Investment ManagersFinance Paramount BioCapital, Inc. is an alternative investment manager. The private company is based in New York, NY and has subsidiaries in the United States. | 19 years |
| Jaclyn Jaffe | F | - | - | |
| Scott Reines | M | 77 | 8 years | |
| Suzanne Lentzsch | M | - |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | - |
| Rodney H. Falk | M | - |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | - |
| Susan Sobolov | M | - |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | 7 years |
| Andrew Zwible | M | - | 4 years | |
| Lynn E. Bayless | F | - | 4 years | |
| Debra Manning | F | - | 5 years | |
| Bruce Dezube | M | - | 3 years | |
| Michael Ryan | M | - | 6 years | |
| Peter Carney | M | 38 | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jose M. Aldeanueva | M | 55 | - | |
| Jeff Paley | M | 55 | 4 years | |
| Robyn Hunter | F | 62 | 11 years | |
| Alan Auerbach | M | 54 |
Cougar Biotechnology, Inc. /Old/
 Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA. | 6 years |
| David J. Horin | M | 56 | 2 years | |
| Bobby Sandage | M | 70 | 2 years | |
| Glenn L. Cooper | M | 71 | 4 years | |
| Harlan Weisman | M | 71 | 1 years | |
| Joseph Vazzano | M | 40 | 5 years | |
| Noah Beerman | M | 62 | 2 years | |
| Raymond Tesi | M | 68 | 3 years | |
| Jack Kaye | M | 80 | 10 years | |
| Gary Gemignani | M | 58 | 1 years | |
| Scott Boilen | M | 57 | 8 years | |
| Barry Rodgers | M | 84 | - | |
| Jeffrey J. Gutovich | M | 67 | - | |
| Nishant Saxena | M | 48 | - | |
| Sadik Kassim | M | - | 2 years | |
| Knut Niss | M | - | - | |
| Elizabeth Ingram | F | 59 | 3 years | |
| Evan Renov | M | - |
Paramount BioCapital, Inc.
Paramount BioCapital, Inc. Investment ManagersFinance Paramount BioCapital, Inc. is an alternative investment manager. The private company is based in New York, NY and has subsidiaries in the United States. | 5 years |
| Thomas G. Moore | M | 72 | 1 years | |
| Jaideep Gogtay | M | 58 | 3 years | |
| Charles R. Eyler | M | 76 |
Cougar Biotechnology, Inc. /Old/
Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA. | 5 years |
| Matthew Wein, | - | - | - | |
| David Barrett | M | 48 | - | |
| Stephen Rocamboli | M | 52 |
Paramount BioCapital, Inc.
Paramount BioCapital, Inc. Investment ManagersFinance Paramount BioCapital, Inc. is an alternative investment manager. The private company is based in New York, NY and has subsidiaries in the United States. | 8 years |
| Stephen B. Pudles | M | 63 | - | |
| Ronald Renaud | M | 55 | 1 years | |
| David Tanen | M | 52 |
Paramount BioCapital, Inc.
Paramount BioCapital, Inc. Investment ManagersFinance Paramount BioCapital, Inc. is an alternative investment manager. The private company is based in New York, NY and has subsidiaries in the United States.
Cougar Biotechnology, Inc. /Old/
Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA. | 8 years |
| Akhtar Samad | M | 64 | 4 years | |
| Ronald Bentsur | M | 58 | 6 years | |
| Morris Laster | M | 60 | 5 years | |
| Michael Rogers | M | 64 | 2 years | |
| Dale Ritter | M | 73 | 2 years | |
| Arthur Asher Kornbluth | M | 64 | 2 years | |
| Arie Belldegrun | M | 74 |
Cougar Biotechnology, Inc. /Old/
Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA. | 6 years |
| Eric Rose | M | 73 | - | |
| I. Craig Henderson | M | 82 | 4 years | |
| Elisabeth Leiderman | M | 47 | 9 years | |
| Craig Anthony Zabala | M | 71 |
D.H. Blair & Co., Inc.
| 1 years |
| Peter Morgan Kash | M | 62 |
Paramount BioCapital, Inc.
Paramount BioCapital, Inc. Investment ManagersFinance Paramount BioCapital, Inc. is an alternative investment manager. The private company is based in New York, NY and has subsidiaries in the United States. | 12 years |
| Sean Power | M | 42 | 5 years | |
| Hadas Reuveni | M | 56 | 3 years | |
| Mark Ziering | M | 58 | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 95 | 95.96% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Lindsay Rosenwald
- Personal Network
